Drug Search Results
More Filters [+]

TPA023

Alternative Names: tpa023, mk-0777, mk0777
Latest Update: 2015-11-26
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: GABA Partial Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TPA023

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Generalized anxiety disorder|Schizophrenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TURNS

P2

Completed

Schizophrenia

2009-09-01

NCT00129441

P2

Completed

Schizophrenia

2008-01-01

MK0777-019

P2

Completed

Generalized anxiety disorder

2003-02-01

MK0777-022

P2

Completed

Generalized anxiety disorder

2003-02-01

Recent News Events

Date

Type

Title